Clindamycin HCl
(Synonyms: 盐酸克林霉素) 目录号 : GC15349A lincosamide antibiotic
Cas No.:21462-39-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | For the first experimental period, 11 mg/kg BW clindamycin hydrochloride are administered IV to all animals (Day 0), after catheterisation of the left cephalic vein. The catheters (18 G×51 mm Abbocath-T) are removed shortly after administration of the drug. Blood samples (3 mL) are collected into plastic tubes by aspiration from the catheterized lateral cephalic vein, prior to (t=0 h) and at 2, 5, 10, 15, 20, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 h after administration. The intravenous catheters are flushed with 2 mL 1% heparinized normal saline after each sampling. On Day 28, all dogs receive one Antirobe capsule (150 mg clindamycin hydrochloride). Dose normalisation from mg/animal to mg/kg BW is carried out in each animal by dividing the total amount of clindamycin received, by its body weight. Blood sample collection is performed, following the technique described above, immediately before (t=0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 h after drug administration. All blood samples are allowed to stand in a dark place for 20 min. After centrifugation at 1500 g for 10 min, at 4°C, the supernatant serum is transferred into 5-mL plastic tubes and is stored at −30°C, pending analysis. |
References: [1]. Batzias GC, et al. Clindamycin bioavailability and pharmacokinetics following oral administration of clindamycin hydrochloride capsules in dogs. Vet J. 2005 Nov;170(3):339-45. |
Clindamycin (hydrochloride) is a semisynthetic lincosamide antibiotic, which inhibits protein synthesis by acting on the 50S ribosomal.
Clindamycin is a classical inhibitor of bacterial protein synthesis, by binding to the 23S ribosomal RNA of the 50S ribosomal subunit[1].
Clindamycin hydrochloride results in fast absorption after oral administration in dogs, with a mean absorption time (MAT) of 0.87 hour, and bioavailability is 72.55%. Clindamycin hydrochloride results in total clearance (CL) of Clindamycin after both IV and oral administration (0.503 vs. 0.458 L/h/kg) in dogs. Clindamycin hydrochloride results in volume of distribution at steady-state (IV) at 2.48 L/kg, indicating a wide distribution of clindamycin in body fluids and tissues. Clindamycin serum concentrations after IV and oral administration remain above 0.5 μg/mL approximately for 10 hours[1]. Clindamycin hydrochloride significantly reduces oral malodor from the dogs' baseline levels through 42 days. Clindamycin hydrochloride also results in significant reductions in dental plaque, dental calculus, and gingival bleeding in dogs[2]. Clindamycin hydrochloride (2.5 mg/Lb), after ultrasonic scaling, root planing, and polishing (USRP), has a significant effect on plaque and pocket depth measures of periodontal disease but not on gingivitis in canine[3]. Clindamycin hydrochloride results in complete remission ratio of 71.4% (15/21) in dogs with canine superficial bacterial pyoderma after treat within 14 to 28 days[4].
References:
[1]. Batzias GC, et al. Clindamycin bioavailability and pharmacokinetics following oral administration of clindamycin hydrochloride capsules in dogs. Vet J. 2005 Nov;170(3):339-45.
[2]. Warrick JM, et al. Effect of clindamycin hydrochloride on oral malodor, plaque, calculus, and gingivitis in dogs with periodontitis. Vet Ther. 2000 Winter;1(1):5-16.
[3]. Nielsen D, et al. Effects of treatment with clindamycin hydrochloride on progression of canine periodontal disease after ultrasonic scaling. Vet Ther. 2000 Summer;1(3):150-8.
[4]. Bloom PB, et al. Efficacy of once-daily clindamycin hydrochloride in the treatment of superficial bacterial pyoderma in dogs. J Am Anim Hosp Assoc. 2001 Nov-Dec;37(6):537-42.
Cas No. | 21462-39-5 | SDF | |
别名 | 盐酸克林霉素 | ||
化学名 | (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;hydrochloride | ||
Canonical SMILES | CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl.Cl | ||
分子式 | C18H33ClN2O5S.HCl | 分子量 | 461.44 |
溶解度 | ≥ 15.35mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1671 mL | 10.8356 mL | 21.6713 mL |
5 mM | 0.4334 mL | 2.1671 mL | 4.3343 mL |
10 mM | 0.2167 mL | 1.0836 mL | 2.1671 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。